APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-Targeted Small Molecules

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global RNA-Targeted Small Molecules Market Analysis and Forecast 2026-2032

1 January 2026196 pages

Choose your research edition.

Industry ResearchRNA-Targeted Small Molecules Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-Targeted Small Molecules Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal RNA-Targeted Small Molecules Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-Targeted Small Molecules Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-Targeted Small Molecules Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global RNA-Targeted Small Molecules market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for RNA-Targeted Small Molecules is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of RNA-Targeted Small Molecules include Twentyeight-Seven Therapeutics, STORM Therapeutics, Skyhawk Therapeutics, Ribometrix, H3 Biomedicine, Gotham Therapeutics, Expansion Therapeutics, Epics Therapeutics and Arrakis Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for RNA-Targeted Small Molecules, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of RNA-Targeted Small Molecules, also provides the revenue of main regions and countries. Of the upcoming market potential for RNA-Targeted Small Molecules, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNA-Targeted Small Molecules revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global RNA-Targeted Small Molecules market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for RNA-Targeted Small Molecules revenue, projected growth trends, production technology, application and end-user industry.

RNA-Targeted Small Molecules Segment by Company

Twentyeight-Seven Therapeutics

STORM Therapeutics

Skyhawk Therapeutics

Ribometrix

H3 Biomedicine

Gotham Therapeutics

Expansion Therapeutics

Epics Therapeutics

Arrakis Pharmaceuticals

Anima Biotech Inc.

Accent Therapeutics

RNA-Targeted Small Molecules Segment by Type

mRNA Translation Regulation

RNA Splicing Modification

Indirect RNA Targeting - Epitranscriptomics

Direct RNA Targeting

RNA-Targeted Small Molecules Segment by Application

Laboratories

Hospitals

Phamacy

RNA-Targeted Small Molecules Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecules and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecules.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of RNA-Targeted Small Molecules in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of RNA-Targeted Small Molecules company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA-Targeted Small Molecules revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNA-Targeted Small Molecules Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. mRNA Translation Regulation Major Player Table 3. RNA Splicing Modification Major Player Table 4. Indirect RNA Targeting - Epitranscriptomics Major Player Table 5. Direct RNA Targeting Major Player Table 6. Global RNA-Targeted Small Molecules Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Laboratories Major Player Table 8. Hospitals Major Player Table 9. Phamacy Major Player Table 10. RNA-Targeted Small Molecules Industry Trends Table 11. RNA-Targeted Small Molecules Industry Drivers Table 12. RNA-Targeted Small Molecules Industry Opportunities and Challenges Table 13. RNA-Targeted Small Molecules Industry Restraints Table 14. Global RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global RNA-Targeted Small Molecules Market Size by Region (2021-2026) & (US$ Million) Table 16. Global RNA-Targeted Small Molecules Market Share by Region (2021-2026) Table 17. Global RNA-Targeted Small Molecules Market Size by Region (2027-2032) & (US$ Million) Table 18. Global RNA-Targeted Small Molecules Market Share by Region (2027-2032) Table 19. Global RNA-Targeted Small Molecules Revenue by Players (US$ Million) & (2021-2026) Table 20. Global RNA-Targeted Small Molecules Revenue Market Share by Players (2021-2026) Table 21. Global RNA-Targeted Small Molecules Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global RNA-Targeted Small Molecules Key Players Headquarters & Area Served Table 23. Global RNA-Targeted Small Molecules Players, Product Type & Application Table 24. Global RNA-Targeted Small Molecules Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global RNA-Targeted Small Molecules by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global RNA-Targeted Small Molecules Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 29. Global RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 30. Global RNA-Targeted Small Molecules Revenue Market Share by Type (2021-2026) Table 31. Global RNA-Targeted Small Molecules Revenue Market Share by Type (2027-2032) Table 32. Global RNA-Targeted Small Molecules Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 34. Global RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 35. Global RNA-Targeted Small Molecules Revenue Market Share by Application (2021-2026) Table 36. Global RNA-Targeted Small Molecules Revenue Market Share by Application (2027-2032) Table 37. Twentyeight-Seven Therapeutics Company Information Table 38. Twentyeight-Seven Therapeutics Business Overview Table 39. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 41. Twentyeight-Seven Therapeutics Recent Development Table 42. STORM Therapeutics Company Information Table 43. STORM Therapeutics Business Overview Table 44. STORM Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 46. STORM Therapeutics Recent Development Table 47. Skyhawk Therapeutics Company Information Table 48. Skyhawk Therapeutics Business Overview Table 49. Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 51. Skyhawk Therapeutics Recent Development Table 52. Ribometrix Company Information Table 53. Ribometrix Business Overview Table 54. Ribometrix RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Ribometrix RNA-Targeted Small Molecules Product Portfolio Table 56. Ribometrix Recent Development Table 57. H3 Biomedicine Company Information Table 58. H3 Biomedicine Business Overview Table 59. H3 Biomedicine RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio Table 61. H3 Biomedicine Recent Development Table 62. Gotham Therapeutics Company Information Table 63. Gotham Therapeutics Business Overview Table 64. Gotham Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 66. Gotham Therapeutics Recent Development Table 67. Expansion Therapeutics Company Information Table 68. Expansion Therapeutics Business Overview Table 69. Expansion Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 71. Expansion Therapeutics Recent Development Table 72. Epics Therapeutics Company Information Table 73. Epics Therapeutics Business Overview Table 74. Epics Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 76. Epics Therapeutics Recent Development Table 77. Arrakis Pharmaceuticals Company Information Table 78. Arrakis Pharmaceuticals Business Overview Table 79. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio Table 81. Arrakis Pharmaceuticals Recent Development Table 82. Anima Biotech Inc. Company Information Table 83. Anima Biotech Inc. Business Overview Table 84. Anima Biotech Inc. RNA-Targeted Small Molecules Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio Table 86. Anima Biotech Inc. Recent Development Table 87. Accent Therapeutics Company Information Table 88. Accent Therapeutics Business Overview Table 89. Accent Therapeutics RNA-Targeted Small Molecules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio Table 91. Accent Therapeutics Recent Development Table 92. North America RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 93. North America RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 94. North America RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 95. North America RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 96. North America RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America RNA-Targeted Small Molecules Revenue by Country (2021-2026) & (US$ Million) Table 98. North America RNA-Targeted Small Molecules Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe RNA-Targeted Small Molecules Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe RNA-Targeted Small Molecules Revenue by Country (US$ Million) & (2027-2032) Table 106. China RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 107. China RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 108. China RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 109. China RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia RNA-Targeted Small Molecules Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia RNA-Targeted Small Molecules Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia RNA-Targeted Small Molecules Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA RNA-Targeted Small Molecules Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA RNA-Targeted Small Molecules Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA RNA-Targeted Small Molecules Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA RNA-Targeted Small Molecules Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA RNA-Targeted Small Molecules Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA RNA-Targeted Small Molecules Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. RNA-Targeted Small Molecules Image Figure 2. Global RNA-Targeted Small Molecules Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-Targeted Small Molecules Market Size Share 2021 VS 2025 VS 2032 Figure 4. mRNA Translation Regulation Image Figure 5. RNA Splicing Modification Image Figure 6. Indirect RNA Targeting - Epitranscriptomics Image Figure 7. Direct RNA Targeting Image Figure 8. Global RNA-Targeted Small Molecules Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global RNA-Targeted Small Molecules Market Size Share 2021 VS 2025 VS 2032 Figure 10. Laboratories Image Figure 11. Hospitals Image Figure 12. Phamacy Image Figure 13. Global RNA-Targeted Small Molecules Market Size (US$ Million) & (2021-2032) Figure 14. Global RNA-Targeted Small Molecules Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global RNA-Targeted Small Molecules Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global RNA-Targeted Small Molecules Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global RNA-Targeted Small Molecules Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global RNA-Targeted Small Molecules Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global RNA-Targeted Small Molecules Revenue Market Share by Type (2021-2032) Figure 21. Global RNA-Targeted Small Molecules Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global RNA-Targeted Small Molecules Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global RNA-Targeted Small Molecules Revenue Market Share by Application (2021-2032) Figure 24. North America RNA-Targeted Small Molecules Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America RNA-Targeted Small Molecules Revenue Share by Type (2021-2032) Figure 26. North America RNA-Targeted Small Molecules Revenue Share by Application (2021-2032) Figure 27. North America RNA-Targeted Small Molecules Revenue Share by Country (2021-2032) Figure 28. United States RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe RNA-Targeted Small Molecules Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe RNA-Targeted Small Molecules Revenue Share by Type (2021-2032) Figure 33. Europe RNA-Targeted Small Molecules Revenue Share by Application (2021-2032) Figure 34. Europe RNA-Targeted Small Molecules Revenue Share by Country (2021-2032) Figure 35. Germany RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China RNA-Targeted Small Molecules Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China RNA-Targeted Small Molecules Revenue Share by Type (2021-2032) Figure 45. China RNA-Targeted Small Molecules Revenue Share by Application (2021-2032) Figure 46. Asia RNA-Targeted Small Molecules Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia RNA-Targeted Small Molecules Revenue Share by Type (2021-2032) Figure 48. Asia RNA-Targeted Small Molecules Revenue Share by Application (2021-2032) Figure 49. Asia RNA-Targeted Small Molecules Revenue Share by Region (2021-2032) Figure 50. Japan RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA RNA-Targeted Small Molecules Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA RNA-Targeted Small Molecules Revenue Share by Type (2021-2032) Figure 58. SAMEA RNA-Targeted Small Molecules Revenue Share by Application (2021-2032) Figure 59. SAMEA RNA-Targeted Small Molecules Revenue Share by Country (2021-2032) Figure 60. Brazil RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt RNA-Targeted Small Molecules Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Translation Regulation
  • RNA Splicing Modification
  • Indirect RNA Targeting - Epitranscriptomics
  • Direct RNA Targeting
Applications
  • Laboratories
  • Hospitals
  • Phamacy
Companies covered
  • Twentyeight-Seven Therapeutics
  • STORM Therapeutics
  • Skyhawk Therapeutics
  • Ribometrix
  • H3 Biomedicine
  • Gotham Therapeutics
  • Expansion Therapeutics
  • Epics Therapeutics
  • Arrakis Pharmaceuticals
  • Anima Biotech Inc.
  • Accent Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 RNA-Targeted Small Molecules Market by Type
  3. 1.2.1 Global RNA-Targeted Small Molecules Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 mRNA Translation Regulation
  5. 1.2.3 RNA Splicing Modification
  6. 1.2.4 Indirect RNA Targeting - Epitranscriptomics
  7. 1.2.5 Direct RNA Targeting
  8. 1.3 RNA-Targeted Small Molecules Market by Application
  9. 1.3.1 Global RNA-Targeted Small Molecules Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Laboratories
  11. 1.3.3 Hospitals
  12. 1.3.4 Phamacy
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 RNA-Targeted Small Molecules Market Dynamics
  1. 2.1 RNA-Targeted Small Molecules Industry Trends
  2. 2.2 RNA-Targeted Small Molecules Industry Drivers
  3. 2.3 RNA-Targeted Small Molecules Industry Opportunities and Challenges
  4. 2.4 RNA-Targeted Small Molecules Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global RNA-Targeted Small Molecules Market Perspective (2021-2032)
  2. 3.2 Global RNA-Targeted Small Molecules Growth Trends by Region
  3. 3.2.1 Global RNA-Targeted Small Molecules Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global RNA-Targeted Small Molecules Market Size by Region (2021-2026)
  5. 3.2.3 Global RNA-Targeted Small Molecules Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global RNA-Targeted Small Molecules Revenue by Players
  2. 4.1.1 Global RNA-Targeted Small Molecules Revenue by Players (2021-2026)
  3. 4.1.2 Global RNA-Targeted Small Molecules Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global RNA-Targeted Small Molecules Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global RNA-Targeted Small Molecules Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global RNA-Targeted Small Molecules Key Players Headquarters & Area Served
  7. 4.4 Global RNA-Targeted Small Molecules Players, Product Type & Application
  8. 4.5 Global RNA-Targeted Small Molecules Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global RNA-Targeted Small Molecules Market CR5 and HHI
  11. 4.6.3 2025 RNA-Targeted Small Molecules Tier 1, Tier 2, and Tier 3
5 RNA-Targeted Small Molecules Market Size by Type
  1. 5.1 Global RNA-Targeted Small Molecules Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 5.3 Global RNA-Targeted Small Molecules Revenue Market Share by Type (2021-2032)
6 RNA-Targeted Small Molecules Market Size by Application
  1. 6.1 Global RNA-Targeted Small Molecules Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  3. 6.3 Global RNA-Targeted Small Molecules Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Twentyeight-Seven Therapeutics
  2. 7.1.1 Twentyeight-Seven Therapeutics Company Information
  3. 7.1.2 Twentyeight-Seven Therapeutics Business Overview
  4. 7.1.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio
  6. 7.1.5 Twentyeight-Seven Therapeutics Recent Developments
  7. 7.2 STORM Therapeutics
  8. 7.2.1 STORM Therapeutics Company Information
  9. 7.2.2 STORM Therapeutics Business Overview
  10. 7.2.3 STORM Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  11. 7.2.4 STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio
  12. 7.2.5 STORM Therapeutics Recent Developments
  13. 7.3 Skyhawk Therapeutics
  14. 7.3.1 Skyhawk Therapeutics Company Information
  15. 7.3.2 Skyhawk Therapeutics Business Overview
  16. 7.3.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio
  18. 7.3.5 Skyhawk Therapeutics Recent Developments
  19. 7.4 Ribometrix
  20. 7.4.1 Ribometrix Company Information
  21. 7.4.2 Ribometrix Business Overview
  22. 7.4.3 Ribometrix RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Ribometrix RNA-Targeted Small Molecules Product Portfolio
  24. 7.4.5 Ribometrix Recent Developments
  25. 7.5 H3 Biomedicine
  26. 7.5.1 H3 Biomedicine Company Information
  27. 7.5.2 H3 Biomedicine Business Overview
  28. 7.5.3 H3 Biomedicine RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  29. 7.5.4 H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio
  30. 7.5.5 H3 Biomedicine Recent Developments
  31. 7.6 Gotham Therapeutics
  32. 7.6.1 Gotham Therapeutics Company Information
  33. 7.6.2 Gotham Therapeutics Business Overview
  34. 7.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio
  36. 7.6.5 Gotham Therapeutics Recent Developments
  37. 7.7 Expansion Therapeutics
  38. 7.7.1 Expansion Therapeutics Company Information
  39. 7.7.2 Expansion Therapeutics Business Overview
  40. 7.7.3 Expansion Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio
  42. 7.7.5 Expansion Therapeutics Recent Developments
  43. 7.8 Epics Therapeutics
  44. 7.8.1 Epics Therapeutics Company Information
  45. 7.8.2 Epics Therapeutics Business Overview
  46. 7.8.3 Epics Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio
  48. 7.8.5 Epics Therapeutics Recent Developments
  49. 7.9 Arrakis Pharmaceuticals
  50. 7.9.1 Arrakis Pharmaceuticals Company Information
  51. 7.9.2 Arrakis Pharmaceuticals Business Overview
  52. 7.9.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio
  54. 7.9.5 Arrakis Pharmaceuticals Recent Developments
  55. 7.10 Anima Biotech Inc.
  56. 7.10.1 Anima Biotech Inc. Company Information
  57. 7.10.2 Anima Biotech Inc. Business Overview
  58. 7.10.3 Anima Biotech Inc. RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio
  60. 7.10.5 Anima Biotech Inc. Recent Developments
  61. 7.11 Accent Therapeutics
  62. 7.11.1 Accent Therapeutics Company Information
  63. 7.11.2 Accent Therapeutics Business Overview
  64. 7.11.3 Accent Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio
  66. 7.11.5 Accent Therapeutics Recent Developments
8 North America
  1. 8.1 North America RNA-Targeted Small Molecules Revenue (2021-2032)
  2. 8.2 North America RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 8.2.1 North America RNA-Targeted Small Molecules Revenue by Type (2021-2026)
  4. 8.2.2 North America RNA-Targeted Small Molecules Revenue by Type (2027-2032)
  5. 8.3 North America RNA-Targeted Small Molecules Revenue Share by Type (2021-2032)
  6. 8.4 North America RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  7. 8.4.1 North America RNA-Targeted Small Molecules Revenue by Application (2021-2026)
  8. 8.4.2 North America RNA-Targeted Small Molecules Revenue by Application (2027-2032)
  9. 8.5 North America RNA-Targeted Small Molecules Revenue Share by Application (2021-2032)
  10. 8.6 North America RNA-Targeted Small Molecules Revenue by Country
  11. 8.6.1 North America RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America RNA-Targeted Small Molecules Revenue by Country (2021-2026)
  13. 8.6.3 North America RNA-Targeted Small Molecules Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe RNA-Targeted Small Molecules Revenue (2021-2032)
  2. 9.2 Europe RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 9.2.1 Europe RNA-Targeted Small Molecules Revenue by Type (2021-2026)
  4. 9.2.2 Europe RNA-Targeted Small Molecules Revenue by Type (2027-2032)
  5. 9.3 Europe RNA-Targeted Small Molecules Revenue Share by Type (2021-2032)
  6. 9.4 Europe RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  7. 9.4.1 Europe RNA-Targeted Small Molecules Revenue by Application (2021-2026)
  8. 9.4.2 Europe RNA-Targeted Small Molecules Revenue by Application (2027-2032)
  9. 9.5 Europe RNA-Targeted Small Molecules Revenue Share by Application (2021-2032)
  10. 9.6 Europe RNA-Targeted Small Molecules Revenue by Country
  11. 9.6.1 Europe RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe RNA-Targeted Small Molecules Revenue by Country (2021-2026)
  13. 9.6.3 Europe RNA-Targeted Small Molecules Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China RNA-Targeted Small Molecules Revenue (2021-2032)
  2. 10.2 China RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 10.2.1 China RNA-Targeted Small Molecules Revenue by Type (2021-2026)
  4. 10.2.2 China RNA-Targeted Small Molecules Revenue by Type (2027-2032)
  5. 10.3 China RNA-Targeted Small Molecules Revenue Share by Type (2021-2032)
  6. 10.4 China RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  7. 10.4.1 China RNA-Targeted Small Molecules Revenue by Application (2021-2026)
  8. 10.4.2 China RNA-Targeted Small Molecules Revenue by Application (2027-2032)
  9. 10.5 China RNA-Targeted Small Molecules Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia RNA-Targeted Small Molecules Revenue (2021-2032)
  2. 11.2 Asia RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 11.2.1 Asia RNA-Targeted Small Molecules Revenue by Type (2021-2026)
  4. 11.2.2 Asia RNA-Targeted Small Molecules Revenue by Type (2027-2032)
  5. 11.3 Asia RNA-Targeted Small Molecules Revenue Share by Type (2021-2032)
  6. 11.4 Asia RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  7. 11.4.1 Asia RNA-Targeted Small Molecules Revenue by Application (2021-2026)
  8. 11.4.2 Asia RNA-Targeted Small Molecules Revenue by Application (2027-2032)
  9. 11.5 Asia RNA-Targeted Small Molecules Revenue Share by Application (2021-2032)
  10. 11.6 Asia RNA-Targeted Small Molecules Revenue by Country
  11. 11.6.1 Asia RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia RNA-Targeted Small Molecules Revenue by Country (2021-2026)
  13. 11.6.3 Asia RNA-Targeted Small Molecules Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA RNA-Targeted Small Molecules Revenue (2021-2032)
  2. 12.2 SAMEA RNA-Targeted Small Molecules Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA RNA-Targeted Small Molecules Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA RNA-Targeted Small Molecules Revenue by Type (2027-2032)
  5. 12.3 SAMEA RNA-Targeted Small Molecules Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA RNA-Targeted Small Molecules Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA RNA-Targeted Small Molecules Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA RNA-Targeted Small Molecules Revenue by Application (2027-2032)
  9. 12.5 SAMEA RNA-Targeted Small Molecules Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA RNA-Targeted Small Molecules Revenue by Country
  11. 12.6.1 SAMEA RNA-Targeted Small Molecules Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA RNA-Targeted Small Molecules Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA RNA-Targeted Small Molecules Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst